EU/3/15/1600 - orphan designation for treatment of hyperargininaemia
sodium benzoate
Orphan
Human
Overview
On 11 January 2016, orphan designation (EU/3/15/1600) was granted by the European Commission to Syri Limited, United Kingdom, for sodium benzoate for the treatment of hyperargininaemia.
The sponsorship was transferred to Syri Pharma Limited, Ireland, in August 2019.
Hyperargininaemia is one of the inherited disorders known as 'urea-cycle disorders', which cause ammonia to accumulate in the blood. Patients with this disorder lack 'arginase', one of the liver enzymes that are needed to get rid of excess nitrogen. In the absence of this liver enzyme, excess nitrogen accumulates in the body in the form of ammonia, which can be toxic at high levels, especially to the brain. Symptoms of the disease usually appear in the first few years of life and include developmental delay, stiffness especially in the legs, vomiting and seizures (fits).
Hyperargininaemia is a long-term debilitating and life-threatening disease that leads to mental disability and is associated with poor overall survival.
At the time of designation, hyperargininaemia affected less than 0.01 in 10,000 people in the European Union (EU). This was equivalent to a total of fewer than 500 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 512,900,000 (Eurostat 2015).
At the time of designation, Ravicti (glycerol phenylbutyrate) was authorised in the EU for the treatment of urea cycle disorders including hyperargininaemia. Patients were generally advised to control their dietary intake of proteins, which are rich in nitrogen, to reduce the amount of ammonia formed in the body. Ravicti is for use in patients who cannot be managed by changes in their diet alone.
The sponsor has provided sufficient information to show that sodium benzoate might be of significant benefit for patients with hyperargininaemia because it could be used together with the currently authorised treatment, and could be beneficial when treating acute forms of the condition. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.
Sodium benzoate has been used as an unlicensed treatment for hyperammonaemia (high levels of ammonia in the blood).
It works by combining with the amino acid glycine, which contains nitrogen, to form a substance that can be removed from the body by the kidneys. This allows the levels of nitrogen in the body to decrease, reducing the amount of ammonia produced and therefore the damage to the brain and other organs.
At the time of submission of the application for orphan designation, no clinical trials with sodium benzoate in patients with hyperargininaemia had been started. The sponsor presented data from the published literature on the use of sodium benzoate in urea cycle disorders.
At the time of submission, sodium benzoate was not authorised anywhere in the EU for hyperargininaemia or designated as an orphan medicinal product elsewhere for this condition.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 10 December 2015 recommending the granting of this designation.
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
Key facts
- Active substance
- sodium benzoate
- Intended use
- Treatment of hyperargininaemia
- Orphan designation status
- Positive
- EU designation number
- EU/3/15/1600
- Date of designation
- Sponsor
Syri Pharma Limited
Floor 0
1 Windmill Lane
Dublin 2
D02 F206
Ireland
E-mail: medinfo@bnsthamelabs.co.uk
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
EMA list of opinions on orphan medicinal product designation
EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: